Celadon Pharmaceuticals PLC (GB:CEL) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Celadon Pharmaceuticals PLC, a UK-based company specializing in cannabis-based medicines, has announced the admission of 2,625,000 new ordinary shares to the AIM market, bringing the total number of ordinary shares to 68,845,807. This development could be of interest to investors tracking the expansion of pharmaceutical companies in the burgeoning field of medicinal cannabis. Celadon is known for its focus on chronic pain treatments and is currently involved in a UK clinical trial for cannabis-based products.
For further insights into GB:CEL stock, check out TipRanks’ Stock Analysis page.
